莪术醇通过抑制PI3K-Akt通路，减轻银屑病HaCaT角化细胞模型中的过度增殖和炎症反应，改善银屑病样小鼠的皮肤病变和炎症状态。

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-10 DOI:10.1007/s10787-025-01708-y

Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao

{"title":"莪术醇通过抑制PI3K-Akt通路，减轻银屑病HaCaT角化细胞模型中的过度增殖和炎症反应，改善银屑病样小鼠的皮肤病变和炎症状态。","authors":"Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao","doi":"10.1007/s10787-025-01708-y","DOIUrl":null,"url":null,"abstract":"Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"2165-2178"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.\",\"authors\":\"Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao\",\"doi\":\"10.1007/s10787-025-01708-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.\",\"PeriodicalId\":13551,\"journal\":{\"name\":\"Inflammopharmacology\",\"volume\":\" \",\"pages\":\"2165-2178\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10787-025-01708-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01708-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

银屑病是一种慢性自身免疫性疾病，以角化细胞增生和炎症反应为特征。姜黄酚是一种生物活性萜类化合物，具有抗增殖和抗炎特性。本研究在体外和体内模型中评估姜黄酚治疗牛皮癣的疗效。在体外实验中，姜黄酚通过抑制PI3K-Akt通路抑制M5细胞因子刺激的银屑病HaCaT角化细胞模型的过度增殖和炎症反应。此外，在体内，姜黄酚可改善吡喹莫德诱导小鼠的牛皮癣样皮肤病变和炎症状态。网络药理学发现姜黄酚的有益作用可能涉及PI3K-Akt信号通路。进一步的研究表明，姜黄酚部分抵消了角化细胞中PI3K-Akt的活化。这些结果表明姜黄酚可能是治疗牛皮癣的一个有希望的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.

Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]